{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-021712","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.182384+00:00","generated_at":"2026-05-16T21:44:25.239603+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Telomir-1 outperforms FDA-approved DFO in reducing intracellular iron in preclinical study","bullets":["Telomir-1 reduced intracellular Fe²⁺ in human keratinocytes in dose- and time-dependent manner at low-micromolar concentrations.","Deferoxamine (DFO) exhibited limited intracellular activity under equivalent conditions.","Telomir-1 formulated with zinc (Telomir-Zn) enables controlled exchange of metal ions – binding excess iron/copper while contributing zinc.","Findings support research into metal-ion balance, oxidative stress, and epigenetic enzyme dynamics in aging and disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-021712","json":"https://secwatch.observer/filing/0001493152-25-021712.json","markdown":"https://secwatch.observer/filing/0001493152-25-021712.md","text":"https://secwatch.observer/filing/0001493152-25-021712.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225021712/0001493152-25-021712-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225021712/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:44:25.239603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}